The anti-Covid vaccines make the shares of manufacturers 'fly', top pharmaceutical producers on the stock market in 2021

2021-02-27T19:05:22.530Z

Vaccines make the stock markets soar as the headlines of major manufacturers testify. Even if they have had falls due to production difficulties, they are holding up the market very well. Pfizer with a capitalization of 186.7 billion dollars, peaking on December 8, 2020, at 42.56 dollars, corresponding to the arrival of the first vaccine loads in some countries, just under 43, 8 dollars on November 30, 2018, the highest in the last five years, then closing last week at 33.4 euros. In 2020, the group recorded revenues of 41.9 billion (+ 7%) and has forecast that the only sales of the vaccine produced with the German BioNTech (revenues of 136.9 million euros in the first 9 months of 2020, + 41%) will generate $ 15 billion in 2021. Moderna, $ 61.8 billion in capitalization, saw its peak in value per share for the past 5 years on February 8, 2021, at $ 185.98, after surging to $ 169. , 8 dollars last December 8, both in moments of start and consolidation of the distribution, closing last week at 154.8 dollars. While the shares of Astrazeneca, which has a capitalization of 91.1 billion pounds, peaked in the last five years on 20 July at 8,320 pounds, with the good news on phase 3 research and the first advance agreements for distribution of 2 billion doses, to close last Friday at 6,954 pounds. Up to now, the rapidly moving price trend has characterized the entire pandemic and pharmaceutical companies more generally. Looking at growth expectations, AstraZeneca closed 2020 with net income more than doubled to $ 3.2 billion and sales to $ 26.6 billion (+ 9%). Johnson & Johnson, also listed in London, with a capitalization of $ 416.5 billion, reached a 5-year peak at $ 179.4 per share on January 26, with the release of the data from the latest testing phase. , closing last week at $ 158.4 in New York.